Browse by author
Lookup NU author(s): Dr Wendy Osborne
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2017 John Wiley & Sons Ltd. Relapsed or refractory classical Hodgkin lymphoma (cHL) is associated with a poor outcome when standard chemotherapy fails. Brentuximab vedotin (BV) is an anti-CD30 monoclonal antibody-drug conjugate licensed for use at relapse after autologous stem cell transplant (ASCT) or following two prior therapies in those unsuitable for ASCT. There are limited data assessing the ability of BV to enable curative SCT. We performed a UK-wide retrospective study of 99 SCT-naïve relapsed/refractory cHL. All had received 2 prior lines and were deemed fit for transplant but had an insufficient remission to proceed. The median age was 32 years. Most had nodular sclerosis subtype, Eastern Cooperative Oncology Group performance status 0-1 and advanced stage disease. The median progression-free survival (PFS) was 5·6 months and median overall survival (OS) was 37·2 months. The overall response rate was 56% (29% complete response; 27% partial response). 61% reached SCT: 34% immediately post-BV and 27% following an inadequate BV response but were salvaged and underwent deferred SCT. Patients consolidated with SCT had a superior PFS and OS to those not receiving SCT (P < 0·001). BV is an effective, non-toxic bridge to immediate SCT in 34% and deferred SCT in 27%. 39% never reached SCT with a PFS of 3·0 months, demonstrating the unmet need to improve outcomes in those unsuitable for SCT post-BV.
Author(s): Eyre TA, Phillips EH, Linton KM, Kassam S, Gibb A, Allibone S, Radford J, Peggs K, Burton C, Stewart G, Ledieu R, Booth C, Osborne WL, Miall F, Eyre DW, Ardeshna KM, Collins GP
Publication type: Article
Publication status: Published
Journal: British Journal of Haematology
Print publication date: 01/11/2017
Online publication date: 31/08/2017
Acceptance date: 18/07/2017
ISSN (print): 0007-1048
ISSN (electronic): 1365-2141
Publisher: John Wiley & Sons Ltd
Altmetrics provided by Altmetric